

27th May 2010

Plethora Solutions Holdings plc
("Plethora" or "the Company")

Result of Annual General Meeting

Plethora Solutions Holdings plc (AIM: PLE), the UK-based specialty pharmaceutical company, announces that all resolutions were duly passed at the Annual General Meeting held earlier today.

-Ends-

Enquiries:

Plethora Solutions

Steven Powell/Ronald Openshaw

Tel : +44(0) 20 3077 5400

FinnCap

Geoff Nash/Marc Young

Tel : +44(0) 20 7600 1658

Hansard Communications

Kirsty Corcoran/John Bick

Tel: +44(0) 20 7245 1100

About Plethora:

Plethora is focused on the development and marketing of products for the treatment of urological disorders. The Company has products in clinical development for the treatment of overactive bladder (PSD506), stress urinary incontinence (PSD503), interstitial cystitis (PSD597), gynaecological pain (PSD508), erectile dysfunction (PSD510) and premature ejaculation (PSD502). Plethora's subsidiary, The Urology Company Limited, was established in 2009 to market and distribute a range of therapeutic products for the treatment of urology, andrology and obstetric conditions. The Company is headquartered in the UK and is listed on the London Stock Exchange (AIM: PLE.L).

Further information is available at www.plethorasolutions.co.uk.